TheraVet: BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA
11 Ottobre 2023 - 7:30AM
Business Wire
- BIOCERA-VET RTU introduced as a breakthrough innovation to
treat horse bone cysts at the World Breeding Federation for
Sport Horses annual meeting (Orlando, USA)
- TheraVet’ sponsor of the gala diner
- Continuation of the efforts in establishing equine
collaborations
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets,
announces its participation at the annual meeting of the World
Breeding Federation for Sport Horses (WBFSH) taking place in
Orlando known as “horse capital of the world” from October
13 to 15 2023, and the sponsorship of its gala dinner.
The annual meeting of the WBFSH, the international umbrella
organization of studbooks, is a leading event gathering more than
100 members representing 17 countries in Orlando. The annual
meeting will cover topics ranging from welfare perspectives to
skeletal conditions.
Dr Hilde Vrancken, Veterinary Advisor Equine of Theravet, will
introduce and highlight the importance of bone cysts, as well as
the availability of a breakthrough innovation to treat them with
BIOCERA-VET RTU. Indeed, the subchondral bone cysts affect 25% of
yearlings (horses in their second year), representing up to 200,000
horses in Europe and US and a common cause of lameness and reduced
performance of young equine athletes. BIOCERA-VET has an
exclusive positioning in its treatment today on the market thanks
to the properties required for minimally invasive cementoplasty
(high injectability, long workability, high radiopacity & high
cohesiveness & fast self-setting).
The Company continues the effort in the establishment of strong
collaboration with renowned clinics and specialized equine
veterinarians with Dierenkliniek Emmeloord, The Netherlands (The
Netherlands, www.dierenkliniekemmeloord.nl) and now with Equitom
clinic (Belgium, www.equitom.be/en/), a clinic part of the Equine
Care Group (www.equinecaregroup.com/en/) with the objective to
gather more patient experience with BIOCERA-VET RTU and also to
design the optimal product for bone cyst management but also for
equine dental and orthopedic surgery in general.
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary. For more
information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter
About BIOCERA-VET In close collaboration with an
international scientific board, THERAVET® has developed a new line
of calcium-phosphate and biological bone substitutes, BIOCERA-VET®.
BIOCERA-VET® is a full range of innovative, easy-to-use, efficient
& cost-effective bone substitutes indicated in bone surgeries
where a bone graft is required and as a palliative alternative in
the management of canine osteosarcoma. Based on extremely promising
clinical results, this line offers the possibility of a better,
more convenient and more efficient orthopedic surgery. BIOCERA-VET®
is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic
delivery calcium-phosphate bone substitute
For more information, visit BIOCERA-VET website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231010765762/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
Grafico Azioni TheraVet (EU:ALVET)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni TheraVet (EU:ALVET)
Storico
Da Mag 2023 a Mag 2024